Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Vaxcyte Inc chart...

About the Company

sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax’s lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax’s broad-spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe

CEO

Grant Pickering

Exchange

NASDAQ

Website

https://vaxcyte.com/

$M

Total Revenue

166

Employees

$7B

Market Capitalization

-20.29

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PCVX News

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

15d ago, source: Business Insider

March 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial ...

Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know

19d ago, source: Zacks.com on MSN

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Q4 2023 Vaxcyte Inc Earnings Call

20d ago, source: Yahoo Finance

Andrew Guggenhime; Chief Financial Officer, Senior Vice President; Vaxcyte Inc Grant Pickering; President, Chief Executive Officer, Director; Vaxcyte Inc James Wassil; Executive Vice President and ...

Vaxcyte Inc Ordinary Shares

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

20d ago, source: Stockhouse

(2024-02-27 | NDAQ:PCVX) Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Stockhouse.com uses cookies on this site. By continuing to use our service, ...

Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript

20d ago, source: Seeking Alpha

My name is Bo and I will be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte Fourth Quarter and Full-Year 2023 Financial Results Conference Call.

Vaxcyte, Inc.: Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

20d ago, source: Finanznachrichten

Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ...

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

20d ago, source: ADVFN

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...